The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function. (D2570-107)
A Study to Evaluate the Pharmacokinetics of D-2570 in Participants With Renal Impairment Compared to Those With Normal Renal Function
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Huan Zhou, Doctor
- Phone Number: 13665527160
- Email: zhouhuanbest@vip.163.com
Study Contact Backup
- Name: Dingli Yao, Bachelor's
- Phone Number: 15538261075
- Email: dingli.yao@inventisbio.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230022
- The First Affiliated Hospital of Anhui Medical University
-
Contact:
- Huan Zhou, Doctor
- Phone Number: 13665527160
- Email: zhouhuanbest@vip.163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily participate in this study after adequate informed consent, sign the written informed consent form, and agree to comply with all procedures specified in the study protocol;
- Aged 18 to 70 years (inclusive). Age matching will be conducted between the normal renal function group and the matched renal impairment group with a mean difference within ±10 years;
- Male and female participants are eligible. Gender matching will be performed between the normal renal function group and the matched renal impairment group with a difference of no more than 1 subject;
- Male participants weigh no less than 50 kg, and female participants weigh no less than 45 kg. Body mass index (BMI) = weight (kg) / height squared (m²), ranging from 19 to 30 kg/m² (inclusive). Weight matching will be conducted between the normal renal function group and the matched renal impairment group with a mean difference within ±10 kg;
Exclusion Criteria:
- Allergic constitution (e.g., allergy to pollen, two or more types of drugs/foods), or history of atopic diseases such as asthma and urticaria, or known hypersensitivity to the study drug or its excipients;
- Positive T-SPOT result at screening. Combined with clinical signs and chest posteroanterior X-ray findings, the participant is judged by the investigator to have active pulmonary tuberculosis;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: participants with normal renal function
Subjects will receive a single dose of D-2570
|
receive a single dose of D-2570
|
|
Experimental: participants with Mild Renal Impairment
Subjects will receive a single dose of D-2570 (Part B)
|
receive a single dose of D-2570
|
|
Experimental: participants with Moderate Renal Impairment
Subjects will receive a single dose of D-2570 (Part A)
|
receive a single dose of D-2570
|
|
Experimental: participants with Severe Renal Impairment
Subjects will receive a single dose of D-2570 (Part A)
|
receive a single dose of D-2570
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The main PK parameters -Time to maximum measured plasma concentration -Tmax
Time Frame: Through study completion (approximately Day9)
|
The main PK parameters -Time to maximum measured plasma concentration -Tmax
|
Through study completion (approximately Day9)
|
|
Maximum observed plasma concentration-Cmax
Time Frame: Through study completion (approximately Day9)
|
Maximum observed plasma concentration-Cmax
|
Through study completion (approximately Day9)
|
|
The main PK parameters Half-life -t1/2
Time Frame: Through study completion (approximately Day9)
|
The main PK parameters Half-life -t1/2
|
Through study completion (approximately Day9)
|
|
The main PK parameters#Area under the plasma concentration versus time curve-AUC
Time Frame: Through study completion (approximately Day9)
|
The main PK parameters#Area under the plasma concentration versus time curve-AUC
|
Through study completion (approximately Day9)
|
|
The main PK parameters-CL/F (apparent clearance)
Time Frame: Through study completion (approximately Day9)
|
The main PK parameters-CL/F (apparent clearance)
|
Through study completion (approximately Day9)
|
|
The main PK parameters-Vz/F (apparent volume of distribution)
Time Frame: Through study completion (approximately Day9)
|
The main PK parameters-Vz/F (apparent volume of distribution)
|
Through study completion (approximately Day9)
|
|
The cumulative excretion amount (Aeu)
Time Frame: Through study completion (approximately Day9)
|
The cumulative excretion (Aeu) of D - 2570 and its metabolites in urine
|
Through study completion (approximately Day9)
|
|
The fraction of drug excreted in urine (Feu)
Time Frame: Through study completion (approximately Day9)
|
The fraction of drug excreted in urine (Feu) of D - 2570 and its metabolites in urine
|
Through study completion (approximately Day9)
|
|
The renal clearance rate (CLR)
Time Frame: Through study completion (approximately Day9)
|
The renal clearance rate (CLR)of D - 2570 and its metabolites in urine
|
Through study completion (approximately Day9)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v6.0
Time Frame: Through study completion (approximately Day9)
|
Incidence of adverse events
|
Through study completion (approximately Day9)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Huan Zhou, Doctor, The First Affiliated Hospital of Anhui Medical University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D2570-107
- CTR20261754 (Other Identifier: Clinicaltrials.gov)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.